Sec Form 4 Filing - Aminov Erez @ Telomir Pharmaceuticals, Inc. - 2025-05-28

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Aminov Erez 2. Issuer Name and Ticker or Trading Symbol Telomir Pharmaceuticals, Inc. [ TELO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO and Chairman (Last) (First) (Middle) C/O TELOMIR PHARMACEUTICALS, INC., 100 SE 2ND ST, SUITE 200 #1009 3. Date of Earliest Transaction (MM/DD/YY) 05/28/2025 (Street) MIAMI,, FL33131 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Non-Qualified Options $ 2.1 ( 1 ) 05/28/2025 A 2,000,000 ( 2 ) 05/28/2035 Common Stock 2,000,000 $ 0 2,000,000 D Restricted Stock Units (RSUs) ( 3 ) 05/28/2025 A 400,000 ( 4 ) ( 5 ) Common Stock 400,000 $ 0 400,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Aminov Erez C/O TELOMIR PHARMACEUTICALS, INC. 100 SE 2ND ST, SUITE 200 #1009 MIAMI,, FL33131 X CEO and Chairman Signatures /s/ Erez Aminov 05/30/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 27, 2025. ( 2 )The stock options were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options are fully vested as of the date of grant. ( 3 )Each restricted stock unit represents a right to receive one share of Issuer's common stock. ( 4 )The RSUs were issued to the Reporting Person on May 28, 2025, pursuant to a grant under the Plan. The RSUs are fully vested as of the date of grant. ( 5 )Each restricted stock unit represents a right to receive one share of Issuer's common stock.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.